Ghose Aruni, Gullapalli Sri Vidya Niharika, Chohan Naila, Bolina Anita, Moschetta Michele, Rassy Elie, Boussios Stergios
Department of Medical Oncology, Barts Cancer Centre, St. Bartholomew's Hospital, Barts Health NHS Trust, London EC1A 7BE, UK.
Department of Medical Oncology, Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust, Northwood HA6 2RN, UK.
Proteomes. 2022 May 9;10(2):16. doi: 10.3390/proteomes10020016.
The ability to identify ovarian cancer (OC) at its earliest stages remains a challenge. The patients present an advanced stage at diagnosis. This heterogeneous disease has distinguishable etiology and molecular biology. Next-generation sequencing changed clinical diagnostic testing, allowing assessment of multiple genes, simultaneously, in a faster and cheaper manner than sequential single gene analysis. Technologies of proteomics, such as mass spectrometry (MS) and protein array analysis, have advanced the dissection of the underlying molecular signaling events and the proteomic characterization of OC. Proteomics analysis of OC, as well as their adaptive responses to therapy, can uncover new therapeutic choices, which can reduce the emergence of drug resistance and potentially improve patient outcomes. There is an urgent need to better understand how the genomic and epigenomic heterogeneity intrinsic to OC is reflected at the protein level, and how this information could potentially lead to prolonged survival.
在卵巢癌（OC）的最早阶段进行识别仍然是一项挑战。患者在诊断时往往已处于晚期。这种异质性疾病具有独特的病因和分子生物学特征。下一代测序改变了临床诊断测试，能够以比顺序单基因分析更快、更便宜的方式同时评估多个基因。蛋白质组学技术，如质谱（MS）和蛋白质阵列分析，推动了对潜在分子信号事件的剖析以及OC的蛋白质组学特征研究。对OC进行蛋白质组学分析及其对治疗的适应性反应，能够发现新的治疗选择，从而减少耐药性的出现并可能改善患者预后。迫切需要更好地了解OC内在的基因组和表观基因组异质性如何在蛋白质水平上得到体现，以及这些信息如何可能带来更长的生存期。
